![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_130,h_50,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_500,h_200,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
A Phase 1 Study of SGN-B6A in Advanced Solid Tumors
This Phase 1 study investigates the safety and tolerability of SGN-B6A in patients with advanced solid tumors. It aims to determine the maximum tolerated dose of the drug while assessing its pharmacokinetics and preliminary effectiveness against various types of advanced solid cancers. The study sets the foundation for further research into SGN-B6A as a potential treatment option for these challenging conditions.
For more information about the trial, click the link below:
Clinical Trial Site: Columbia
To see all available clinical trials click here.
Comments